Neogen Corporation Q3 2026 Earnings Report and Conference Call

The provided sources detail Neogen’s Q3 2026 financial performance and the strategic transformation currently underway within the organization. While the company reported a successful earnings beat in both revenue and profit, the reports highlight a contrast between strong growth in food safety and supply chain disruptions that hindered the animal safety segment. Management is actively implementing a three-pillar strategy focused on commercial prowess, operational efficiency, and high-impact innovation to stabilize long-term results. Key developments include the planned divestiture of their genomics unit for $160 million and the transition of Petrifilm manufacturing to an in-house facility. Despite facing macroeconomic headwinds such as rising freight costs and currency fluctuations, the company raised its full-year revenue guidance. Ultimately, these documents serve as a comprehensive overview of Neogen's operational recovery and its efforts to enhance shareholder value through disciplined cost management.